REVANCE THERAPEUTICS 96 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against
REVANCE THERAPEUTICS 96 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC
PR Newswire
NEW ORLEANS, Feb. 4, 2022
NEW ORLEANS, Feb. 4, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
What You May Do
If you purchased shares of Revance and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-rvnc/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by February 8, 2022.
About the Lawsuit
Revance and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On October 12, 2021, the Company disclosed that on July 2, 2021, the FDA had notified it of problems observed during its inspection of the Company's Northern California DAXI manufacturing facility, including that "[t]he current manufacturing process is not the process proposed for licensure" and that the "Quality Unit lacks the responsibility and authority for control, review, and approval for outsourced activities[.]"
On this news, shares of Revance fell $6.85 per share, or 25%, to close at $20.45 per share on October 12, 2021.
The case is Aramic LLC v. Revance Therapeutics, Inc., No. 21-cv-09585.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163
View original content to download multimedia:https://www.prnewswire.com/news-releases/revance-therapeutics-96-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick--foti-llc-remind-investors-with-losses-in-excess-of-100-000-of-deadline-in-class-action-lawsuit-against-revance-therapeutics-inc----301475992.html
SOURCE Kahn Swick & Foti, LLC
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.